{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.817","value":"-28.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.770","value":"-35.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.700","value":"-38.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.957","value":"-47.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.377","value":"-44.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"title":"Cycle 23, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.952","value":"-44.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.274","value":"-45.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Cycle 35, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.812","value":"-51.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Cycle 41, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.580","value":"-52.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"Cycle 47, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.498","value":"-42.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Cycle 53, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.396","value":"-40.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Cycle 59, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.884","value":"-40.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 65, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"Assessment of spleen volume was performed using serial imaging with MRI. Response was defined as ≥35% reduction in spleen volume (PR) or resolution of palpable splenomegaly (CR). Each cycle is 28 days long.","dispersionType":"Standard Deviation","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEAN","populationDescription":"Safety Population: all participants who received ≥1 dose of avapritinib. Here, 'Number Analyzed' signifies those participants evaluable for this outcome measure at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline up to Month 65","title":"Percent Change From Baseline in Spleen Volume by Imaging","type":"SECONDARY","unitOfMeasure":"Percent Change"}